<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chemotherapy II: Specific Infections & Malignancy - Pharmacology Study Guide</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="../styles/main.css">
    
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <!-- Floating Table of Contents -->
    <div class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span>
            <span>Contents</span>
        </div>
        <ul class="floating-toc-list">
            <!-- JS will populate this -->
        </ul>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>ü¶†</span>
                        <span>Section XII (Part B)</span>
                    </div>
                    <h1 class="document-title">Chemotherapy: Specific Infections & Malignancy</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>TB, Leprosy, Malaria, HIV, Fungal, Helminths & Cancer</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>120 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- START: Chapter 50 -->
                    <section class="content-section" id="chapter-50">
                        <div class="section-header">
                            <div class="section-number">50</div>
                            <h2 class="section-title">
                                <span class="title-icon">üçÑ</span>
                                Antifungal Agents
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Classification</h3>
                            <div class="grid grid-2">
                                <div class="grid-item">
                                    <h4>Polyenes (Antibiotics)</h4>
                                    <p><strong>Amphotericin B, Nystatin.</strong> Bind to ergosterol in fungal cell membrane, creating pores and increasing permeability.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Azoles (Synthetic)</h4>
                                    <p><strong>Imidazoles:</strong> Ketoconazole, Miconazole, Clotrimazole.<br>
                                    <strong>Triazoles:</strong> Fluconazole, Itraconazole, Voriconazole.<br>
                                    Inhibit ergosterol synthesis (14-alpha-demethylase).</p>
                                </div>
                            </div>

                            <h3>Specific Drugs</h3>
                            <p><strong>Amphotericin B:</strong> Gold standard for systemic mycoses (Cryptococcus, Histoplasma, Aspergillus). Highly toxic (Nephrotoxicity, infusion reactions). Liposomal preparations reduce toxicity.</p>
                            <p><strong>Fluconazole:</strong> High oral bioavailability, good CSF penetration. Drug of choice for Cryptococcal meningitis and Candidiasis.</p>
                            <p><strong>Ketoconazole:</strong> Inhibits human steroid synthesis (Anti-androgenic). Used in Cushing's syndrome.</p>
                            <p><strong>Griseofulvin:</strong> Keratophilic. Deposited in keratin precursor cells. Used for Dermatophytosis (Ringworm). Induces CYP450.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 50 -->

                    <!-- START: Chapter 54 -->
                    <section class="content-section" id="chapter-54">
                        <div class="section-header">
                            <div class="section-number">54</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü´Å</span>
                                Chemotherapy of Tuberculosis
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>First Line Drugs</h3>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Drug</th>
                                            <th>Action</th>
                                            <th>Mechanism</th>
                                            <th>Key Adverse Effects</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Isoniazid (H)</strong></td>
                                            <td>Bactericidal</td>
                                            <td>Inhibits mycolic acid synthesis</td>
                                            <td>Peripheral neuropathy (prevent with Pyridoxine), Hepatotoxicity</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Rifampicin (R)</strong></td>
                                            <td>Bactericidal</td>
                                            <td>Inhibits DNA-dependent RNA polymerase</td>
                                            <td>Hepatotoxicity, Red/Orange urine, Enzyme induction</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Pyrazinamide (Z)</strong></td>
                                            <td>Bactericidal (Intracellular)</td>
                                            <td>Unknown (active at acid pH)</td>
                                            <td>Hepatotoxicity, Hyperuricemia (Gout)</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Ethambutol (E)</strong></td>
                                            <td>Bacteriostatic</td>
                                            <td>Inhibits arabinosyl transferase</td>
                                            <td>Optic neuritis (Red-green color blindness), Hyperuricemia</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Streptomycin (S)</strong></td>
                                            <td>Bactericidal</td>
                                            <td>Inhibits protein synthesis (30S)</td>
                                            <td>Ototoxicity, Nephrotoxicity</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>

                            <h3>Treatment Regimens (DOTS)</h3>
                            <p><strong>New Cases (Category I):</strong> <strong>2 (HRZE)<sub>3</sub> + 4 (HR)<sub>3</sub></strong>. (Intensive phase: 2 months of 4 drugs; Continuation phase: 4 months of 2 drugs). All given thrice weekly.</p>
                            <p><strong>MDR-TB:</strong> Resistance to both Isoniazid and Rifampicin. Requires treatment with Second Line drugs (Kanamycin, Fluoroquinolones, Ethionamide, Cycloserine, PAS) for 24 months.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 54 -->

                    <!-- START: Chapter 55 -->
                    <section class="content-section" id="chapter-55">
                        <div class="section-header">
                            <div class="section-number">55</div>
                            <h2 class="section-title">
                                <span class="title-icon">üéóÔ∏è</span>
                                Chemotherapy of Leprosy
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Drugs</h3>
                            <ul>
                                <li><strong>Dapsone (DDS):</strong> Folate synthesis inhibitor (like sulfonamides). Bacteriostatic. ADR: Hemolysis (G6PD deficiency), Lepra reaction.</li>
                                <li><strong>Rifampicin:</strong> Rapidly bactericidal. Kills 99.9% bacilli in days.</li>
                                <li><strong>Clofazimine:</strong> Dye with anti-inflammatory properties. Useful in Lepra reactions (ENL). Causes skin pigmentation (red/black).</li>
                            </ul>

                            <h3>Multidrug Therapy (MDT) Protocols</h3>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Type</th>
                                            <th>Regimen</th>
                                            <th>Duration</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Paucibacillary (PB)</strong></td>
                                            <td>Rifampicin (600mg monthly)<br>Dapsone (100mg daily)</td>
                                            <td>6 months</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Multibacillary (MB)</strong></td>
                                            <td>Rifampicin (600mg monthly)<br>Clofazimine (300mg monthly + 50mg daily)<br>Dapsone (100mg daily)</td>
                                            <td>12 months</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 55 -->

                    <!-- START: Chapter 56 -->
                    <section class="content-section" id="chapter-56">
                        <div class="section-header">
                            <div class="section-number">56</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü¶ü</span>
                                Chemotherapy of Malaria
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Drug Classification by Action</h3>
                            <ul>
                                <li><strong>Erythrocytic Schizonticides (Clinical Cure):</strong> Chloroquine, Quinine, Mefloquine, Artemisinins. (Treat the acute attack).</li>
                                <li><strong>Tissue Schizonticides (Radical Cure):</strong> Primaquine. (Kills hypnozoites in liver for <em>P. vivax/ovale</em>).</li>
                                <li><strong>Gametocidals:</strong> Primaquine (kills gametocytes, prevents transmission).</li>
                            </ul>

                            <h3>Specific Drugs</h3>
                            <p><strong>Chloroquine:</strong> Concentrates in parasite food vacuole, prevents polymerization of toxic heme to hemozoin. Drug of choice for sensitive malaria and pregnancy.</p>
                            <p><strong>Primaquine:</strong> Radical cure (14 days). Risk of hemolysis in <strong>G6PD deficiency</strong>. Contraindicated in pregnancy.</p>
                            <p><strong>Artemisinin Derivatives (Artesunate, Artemether):</strong> Fastest acting. Producing free radicals. First line for **Severe/Cerebral Malaria** and Chloroquine-resistant malaria (ACT - Artemisinin Combination Therapy).</p>
                            <p><strong>Mefloquine:</strong> Long half-life. Neuropsychiatric side effects.</p>

                            <div class="callout callout--danger">
                                <div class="callout-header">
                                    <span class="callout-icon">üöë</span>
                                    <h4 class="callout-title">Severe Falciparum Malaria</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Medical emergency. Treatment: <strong>IV Artesunate</strong> (preferred) or IV Quinine. Watch for hypoglycemia (Quinine stimulates insulin).</p>
                                </div>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 56 -->

                    <!-- START: Chapter 57 -->
                    <section class="content-section" id="chapter-57">
                        <div class="section-header">
                            <div class="section-number">57</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü¶†</span>
                                Amoebiasis and Giardiasis
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Amoebicides</h3>
                            <ul>
                                <li><strong>Tissue Amoebicides:</strong> Metronidazole, Tinidazole, Emetine, Chloroquine (Liver only). Used for invasive dysentery and liver abscess.</li>
                                <li><strong>Luminal Amoebicides:</strong> Diloxanide furoate, Iodoquinol. Used to treat cyst passers and after tissue amoebicides to prevent relapse.</li>
                            </ul>

                            <p><strong>Metronidazole:</strong> Drug of choice for Amoebiasis, Giardiasis, Trichomoniasis, and Anaerobic bacterial infections.
                            <br><strong>Mechanism:</strong> Nitro group reduction forms toxic radicals producing DNA damage.
                            <br><strong>ADR:</strong> Metallic taste, Disulfiram-like reaction with alcohol, Neuropathy.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 57 -->

                    <!-- START: Chapter 53 & 59 -->
                    <section class="content-section" id="chapter-59">
                        <div class="section-header">
                            <div class="section-number">53 & 59</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Antiviral Drugs and HIV
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Anti-Herpes Drugs</h3>
                            <p><strong>Acyclovir:</strong> Activated by viral thymidine kinase. Inhibits viral DNA polymerase. Drug of choice for HSV and VZV.</p>

                            <h3>Anti-Influenza Drugs</h3>
                            <p><strong>Oseltamivir (Tamiflu):</strong> Neuraminidase inhibitor. Prevents release of virus.</p>

                            <h3>Anti-Retroviral Drugs (HIV)</h3>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Class</th>
                                            <th>Examples</th>
                                            <th>Mechanism/Notes</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>NRTI</strong></td>
                                            <td>Zidovudine (AZT), Lamivudine (3TC), Tenofovir</td>
                                            <td>Nucleoside Reverse Transcriptase Inhibitors. Need phosphorylation. Mitochondrial toxicity (Lactic acidosis).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>NNRTI</strong></td>
                                            <td>Nevirapine, Efavirenz</td>
                                            <td>Non-Nucleoside RTI. Bind directly to enzyme. Rash, Hepatotoxicity.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Protease Inhibitors</strong></td>
                                            <td>Ritonavir, Indinavir, Lopinavir</td>
                                            <td>Prevent viral maturation. Lipodystrophy, metabolic syndrome. Ritonavir used as "booster".</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Integrase Inhibitors</strong></td>
                                            <td>Raltegravir</td>
                                            <td>Prevent integration of viral DNA into host genome.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                            <p><strong>HAART:</strong> Highly Active Anti-Retroviral Therapy. Usually 2 NRTIs + 1 NNRTI or 1 PI.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 59 -->

                    <!-- START: Chapter 60 -->
                    <section class="content-section" id="chapter-60">
                        <div class="section-header">
                            <div class="section-number">60</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü™±</span>
                                Chemotherapy of Helminthiasis
                            </h2>
                        </div>

                        <div class="content-card">
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Worm</th>
                                            <th>Drug of Choice</th>
                                            <th>Mechanism</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Roundworm, Hookworm, Pinworm</strong></td>
                                            <td><strong>Albendazole</strong> / Mebendazole</td>
                                            <td>Inhibit microtubule synthesis (glucose uptake block).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Tapeworm (Taenia), Schistosomes</strong></td>
                                            <td><strong>Praziquantel</strong></td>
                                            <td>Increases membrane permeability to Calcium (paralysis).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Filaria</strong></td>
                                            <td><strong>Diethylcarbamazine (DEC)</strong></td>
                                            <td>Sensitizes microfilariae to phagocytosis.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Onchocerca, Strongyloides</strong></td>
                                            <td><strong>Ivermectin</strong></td>
                                            <td>GABA agonist (Paralysis).</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 60 -->

                    <!-- START: Chapter 61 -->
                    <section class="content-section" id="chapter-61">
                        <div class="section-header">
                            <div class="section-number">61</div>
                            <h2 class="section-title">
                                <span class="title-icon">üéóÔ∏è</span>
                                Cancer Chemotherapy (Brief)
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Principles:</strong> Kill rapidly dividing cells. Low therapeutic index. Combination therapy used to prevent resistance and reduce toxicity.</p>
                            
                            <div class="grid grid-2">
                                <div class="grid-item">
                                    <h4>Alkylating Agents</h4>
                                    <p><strong>Cyclophosphamide, Cisplatin.</strong> Cross-link DNA. Cell cycle non-specific. Toxicity: Bone marrow depression, Cystitis (Cyclophosphamide - Acrolein).</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Antimetabolites</h4>
                                    <p><strong>Methotrexate</strong> (Folate antagonist), <strong>5-Fluorouracil</strong> (Pyrimidine antagonist). S-phase specific.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Microtubule Inhibitors</h4>
                                    <p><strong>Vinca Alkaloids (Vincristine):</strong> Inhibit polymerization. M-phase specific. Neurotoxicity.<br>
                                    <strong>Taxanes (Paclitaxel):</strong> Stabilize microtubules.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Antibiotics</h4>
                                    <p><strong>Doxorubicin:</strong> DNA intercalation. Cardiotoxicity.<br>
                                    <strong>Bleomycin:</strong> Pulmonary fibrosis.</p>
                                </div>
                            </div>
                        </div>
                    </section>
                    <!-- END: Chapter 61 -->

                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="section-12.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Section XII (Part A): General Antibiotics</div>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>12b</span>
                                <span class="progress-separator">/</span>
                                <span>16</span>
                            </div>
                        <a href="../index.html" class="nav-button nav-button--large">
                            <div class="nav-label">Go to</div>
                            <div class="nav-title">Index</div>
                        </a>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 80%;"></div>
                            </div>
                            <div class="progress-label">Section 12 (Part B) of 16</div>
                        </div>
                        
                        <a href="section-13.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Section XIII: Endocrine Drugs</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <!-- Lightbox Modal -->
    <div class="lightbox-modal" id="lightbox-modal" role="dialog" aria-modal="true" aria-label="Image viewer" hidden>
        <div class="lightbox-backdrop"></div>
        <div class="lightbox-content">
            <button class="lightbox-close" aria-label="Close image viewer">√ó</button>
            <img class="lightbox-image" src="" alt="">
            <p class="lightbox-caption"></p>
        </div>
    </div>

    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>